Janux Therapeutics
JANX
17.92
+1.13
+6.73%
Janux Therapeutics
US · JANX
#3187 by market cap
Listed 2021
17.92
+1.13
+6.73%
Live - 5344 symbols - heartbeat 526s ago
· 2026-10-08 08:14
Pre-market
18.42
+2.79%
After-hours
18.50
+3.24%
Overnight
17.91
-0.06%
- Market cap
- 1.10B
- P/E (TTM)i
- -10.93
- P/Bi
- 1.18
- EPSi
- -1.83
- Div yieldi
- 0.00%
- 52W posi
- 25%
Reader sentiment
Are you bullish or bearish on JANX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 14.83, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year -5.55% YoY
Margins
- Operating margin
- -1,576.67%
- Net margin
- -1,136.25%
Key ratios & quality
- Altman Z-Scorei
- 14.83
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 3.64M | 8.61M | 8.08M | 10.59M | 10.00M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 772.00K | 1.80M | 10.33M | 22.26M | 26.14M | 41.05M | 41.77M |
| Research & development | 3.00M | 3.04M | 26.24M | 53.44M | 54.92M | 68.39M | 125.90M |
| Operating profit | -3.77M | -4.84M | -32.93M | -67.09M | -72.98M | -98.85M | -157.67M |
| Pretax profit | -4.00M | -6.78M | -32.67M | -63.06M | -58.29M | -68.99M | -113.63M |
| Tax | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -4.00M | -6.78M | -32.67M | -63.06M | -58.29M | -68.99M | -113.63M |
| Basic EPS | -1 | -1 | -1 | -2 | -1 | -1 | -2 |
| Diluted EPS | -0.62 | -0.54 | -1.39 | -1.52 | -1.32 | -1.28 | -1.83 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 10.00M | 0 | 3.73M | 10.27M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 9.84M | 10.45M | 10.62M | 10.85M | 11.13M | 10.96M |
| Research & development | 25.06M | 34.66M | 34.63M | 31.55M | 26.81M | 30.99M |
| Operating profit | -34.90M | -45.12M | -35.25M | -42.40M | -34.21M | -31.69M |
| Pretax profit | -23.51M | -33.86M | -24.31M | -31.95M | -24.36M | -21.97M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -23.51M | -33.86M | -24.31M | -31.95M | -24.36M | -21.97M |
| Basic EPS | 0 | -1 | 0 | -1 | 0 | 0 |
| Diluted EPS | -0.38 | -0.55 | -0.39 | -0.51 | -0.39 | -0.35 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 658.00K | 16.06M | 377.02M | 332.44M | 349.24M | 1.03B | 975.89M |
| Cash & ST investments | 658.00K | 7.81M | 374.97M | 327.02M | 344.03M | 1.03B | 966.57M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 679.00K | 16.22M | 379.82M | 364.01M | 380.41M | 1.06B | 1.00B |
| Total current liabilities | 4.63M | 3.18M | 12.80M | 16.51M | 13.03M | 17.46M | 25.00M |
| Short-term debt | 4.00M | -- | 194.00K | 763.00K | 1.52M | 1.75M | 2.39M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 8,623,000.00 | 30,855,000.00 | 13,497,000.00 | 43,270,000.00 | 36,058,000.00 | 38,735,000.00 | 44,743,000.00 |
| Total equity | -7.94M | -14.64M | 366.33M | 320.74M | 344.35M | 1.02B | 956.82M |
| Retained earnings | -7.96M | -14.74M | -47.41M | -110.47M | -168.76M | -237.76M | -351.38M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.02B | 1.01B | 998.09M | 975.89M | 1.00B | 983.34M |
| Cash & ST investments | 1.01B | 996.01M | 988.99M | 966.57M | 956.39M | 970.91M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.05B | 1.03B | 1.02B | 1.00B | 1.03B | 1.01B |
| Total current liabilities | 17.50M | 21.38M | 27.83M | 25.00M | 58.92M | 60.15M |
| Short-term debt | 1.81M | 1.87M | 2.28M | 2.39M | 2.47M | 2.55M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 38,303,000.00 | 41,696,000.00 | 48,211,000.00 | 44,743,000.00 | 86,690,000.00 | 79,669,000.00 |
| Total equity | 1.01B | 990.52M | 976.56M | 956.82M | 941.54M | 927.98M |
| Retained earnings | -261.27M | -295.12M | -319.44M | -351.38M | -375.74M | -397.72M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -3.83M | -4.37M | -16.98M | -42.92M | -50.58M | -43.81M | -82.24M |
| Depreciation & amortization | 6.00K | 13.00K | 113.00K | 841.00K | 1.96M | 2.06M | 2.03M |
| Free cash flow | -3.83M | -4.37M | -18.46M | -49.37M | -52.43M | -44.17M | -83.28M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 204.17M | 0 | 56.53M | 698.27M | -347.00K |
| Ending cash balance | 658.00K | 7.81M | 36.40M | 52.24M | 20.02M | 431.42M | 53.15M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -17.02M | -23.81M | -12.86M | -28.54M | -12.34M | 12.48M |
| Depreciation & amortization | 519.00K | 541.00K | 501.00K | 468.00K | 469.00K | 463.00K |
| Free cash flow | -17.40M | -24.29M | -12.95M | -28.65M | -12.61M | 12.28M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -347.00K | 0 | 0 | 0 | 0 | 0 |
| Ending cash balance | 74.56M | 53.26M | 49.21M | 53.15M | 52.64M | 28.58M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -18.58 | -18.36 | -17.53 | -10.09 | -11.48 |
| ROA %i | -589.69 | -80.30 | -16.50 | -16.96 | -15.66 | -9.57 | -11.02 |
| ROIC %i | -- | -- | -18.71 | -18.20 | -20.42 | -13.97 | -15.57 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -15.21 |
| EBIT margin %i | -- | -- | -898.32 | -779.04 | -902.87 | -933.58 | -1,576.67 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.14 | 5.05 | 29.46 | 20.14 | 26.80 | 59.21 | 39.04 |
| Quick ratioi | 0.14 | 4.97 | 29.30 | 19.81 | 26.56 | 59.03 | 38.92 |
| Debt / assetsi | 589.10 | 0.00 | 0.05 | 6.95 | 6.45 | 2.17 | 2.21 |
| LT debt / equityi | -- | -- | -- | 7.65 | 6.69 | 2.08 | 2.06 |
| Interest coveragei | -16.18 | -31.93 | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | 42.79 | 5.11 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -9.32 | -12.82 | -12.48 | -11.48 | -11.72 | -10.70 |
| ROA %i | -8.94 | -12.26 | -11.85 | -11.02 | -11.01 | -10.06 |
| ROIC %i | -13.25 | -17.10 | -17.19 | -15.57 | -15.71 | -14.64 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,216.61 | -33,002.05 | -1,442.88 | -1,576.67 | -1,143.11 | -598.15 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 58.47 | 47.03 | 35.86 | 39.04 | 17.01 | 16.35 |
| Quick ratioi | 58.26 | 46.85 | 35.76 | 38.92 | 16.95 | 16.25 |
| Debt / assetsi | 2.15 | 2.15 | 2.21 | 2.21 | 2.10 | 2.08 |
| LT debt / equityi | 2.05 | 2.05 | 2.09 | 2.06 | 2.03 | 1.99 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research and development of a broad pipeline of novel immunotherapies100.00%
Quote time 2026-10-08 08:14:51 · For reference only, not investment advice and not tailored to your situation.